Innovent Biologics Inc (6IB) — Cash Flow Reinvestment Rate
Innovent Biologics Inc (6IB) has a Cash Flow Reinvestment Rate of 9.11x as of December 2020, reinvesting €1.99 Billion (capex €211.14 Million plus investments €-1.78 Billion) from operating cash flow of €217.96 Million. See 6IB cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Innovent Biologics Inc Cash Flow Reinvestment Rate (2023–2025)
Historical reinvestment intensity for Innovent Biologics Inc across 3 annual periods. For the full cash flow conversion analysis, see 6IB cash flow metrics.
Annual Cash Flow Reinvestment Rate for Innovent Biologics Inc (2023–2025)
Year-by-year capital reinvestment analysis for Innovent Biologics Inc. See 6IB financial flexibility score to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.71x | €7.06 Billion | €10.00 Billion | €683.27 Million | ▼ -48.8% |
| 2024 | 1.38x | €1.78 Billion | €1.29 Billion | €1.71 Billion | ▼ -86.9% |
| 2023 | 10.51x | €1.55 Billion | €147.81 Million | €1.38 Billion | — |